ACTERO LAUNCHES DOXORUBICIN ACTE AND ETOPOSIDE ACTE

April 15, 2018

Author: Acteropharma

Actero Middle East is pleased to announce the launch of two new molecules to the Iranian market. Doxorubicin ACTe 10 mg and 50 mg and Etoposide ACTe 100 mg/5ml. Doxorubicin ACTe 10mg and 50mg injections are the generic version of Adriamycin, a chemotherapy medication used to treat a broad range of cancers including breast cancer, bladder cancer, Kaposi’s sarcoma, lymphoma, and acute lymphocytic leukemia. Etoposide ACTe 100 mg/5ml injections are the generic version of Etopophos, a chemotherapy medication used to treat a broad range of cancers including testicular cancer, lung cancer, lymphoma, leukemia, neuroblastoma, and ovarian cancer. “Doxorubicin ACTe and Etoposide ACTe are the two latest products in our growing oncology portfolio. With these new additions, we aim to gain the trust of all stakeholders and continue building a portfolio where every Actero medicine stands for reliability.” CEO of Actero Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

Last News

EHA 2023 Actero Sponsorship

EHA 2023
June 26, 2023

Author:

Acteropharma

Actero Support in Congress 1400

Site
July 24, 2022

Author:

Acteropharma
Actero company’s social respomsibility of patient support in Hematology-Oncology Congress and Radiation Therapy Congress

Best of ASCO 2021

Dr-noroozi-event-2048x1367
November 16, 2021

Author:

Acteropharma
The aforesaid seminar has been held for the first time in Iran with the hospitality of Isfahan city, with the cooperation of Radiation-Oncologists from all over of the country and Actero Pharma.